# Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

> **NCT01419717** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 129 (actual)

## Conditions studied

- Bone Metastases in Men With Hormone-Refractory Prostate Cancer
- Bone Metastases in Subjects With Advanced Breast Cancer

## Interventions

- **DRUG:** Denosumab

## Key facts

- **NCT ID:** NCT01419717
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-22
- **Primary completion:** 2018-08-10
- **Final completion:** 2018-08-10
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2019-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01419717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01419717, "Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01419717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*